OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

MORPHOSYS AG O.N./  DE0006632003  /

Stuttgart
2024-04-25  9:55:32 PM Chg. -0.050 Volume Bid10:05:00 PM Ask10:05:00 PM Market Capitalization Dividend Y. P/E Ratio
67.650EUR -0.07% 2,340
Turnover: 158,430		 -Bid Size: - -Ask Size: - 2.55 bill.EUR - -
TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal
TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B
GlobeNewswire 2021-08-11 Royalty Pharma Reports Second Quarter 2021 Results
GlobeNewswire 2021-06-03 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire 2021-06-02 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire 2020-04-27 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire 2019-10-28 MOR106 clinical development in atopic dermatitis stopped for futility
GlobeNewswire 2019-04-23 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 2019-04-23 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 2019-01-31 Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
GlobeNewswire 2018-09-13 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 2018-09-13 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 2018-09-12 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 2018-09-12 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 2018-07-19 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 2018-07-19 Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atop...
GlobeNewswire 2018-07-19 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 2018-05-01 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 2018-05-01 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 2018-04-19 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
GlobeNewswire 2018-02-17 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 2018-02-17 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 2017-09-27 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 2017-09-27 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...